<div id="readability-page-1"><p>Phreesia, Inc. (NYSE:PHR - Get Free Report) shares gapped down before the market opened on Wednesday . The stock had previously closed at $9.17, but opened at $8.84. Phreesia shares last traded at $8.7870, with a volume of 367,992 shares trading hands.</p><h2>Key Headlines Impacting Phreesia</h2><ul><li>Phreesia Hits Bottom in Q1: Rebound Ahead, Timing Uncertain</li></ul><p>Here are the key news stories impacting Phreesia this week:</p><ul>   <li><span>Negative Sentiment: </span>Multiple law firms are publicizing a class action lawsuit against Phreesia, increasing legal uncertainty and potentially pressuring sentiment. <i></i><span>Article Title</span></li>   <li><span>Negative Sentiment: </span>The allegations focus on possible misstatements about growth durability and the AccessOne acquisition, which could raise concerns about management credibility. <i></i><span>Article Title</span></li>   <li><span>Neutral Sentiment: </span>Several firms are reminding investors of upcoming lead-plaintiff deadlines, but these notices mainly reinforce the already-known litigation overhang. <i></i><span>Article Title</span></li> </ul><h2>Analysts Set New Price Targets</h2><p>Several brokerages have recently issued reports on PHR. Wells Fargo &amp; Company  reissued an &#34;equal weight&#34; rating and set a $9.00 price target (down from $15.00) on shares of Phreesia in a report on Wednesday. JPMorgan Chase &amp; Co.  reissued a &#34;neutral&#34; rating and set a $16.00 price target (down from $24.00) on shares of Phreesia in a report on Tuesday, March 31st. DA Davidson reduced their price target on shares of Phreesia from $35.00 to $30.00 and set a &#34;buy&#34; rating for the company in a report on Friday, January 23rd. Stephens reduced their price target on shares of Phreesia from $32.00 to $20.00 and set an &#34;overweight&#34; rating for the company in a report on Tuesday, March 31st. Finally, Robert W. Baird  reissued a &#34;neutral&#34; rating and set a $10.00 price target (down from $25.00) on shares of Phreesia in a report on Tuesday, March 31st. Ten research analysts have rated the stock with a Buy rating, eight have issued  a Hold rating and one  has assigned  a Sell rating to the stock. Based on data from MarketBeat.com, the company  has a consensus rating of &#34;Hold&#34; and a consensus target price of $19.06.</p><ul><li>Can Waystar Still Stand Up to Rising Competition?</li></ul><p><b>View Our Latest Research Report on PHR</b></p><h2>Phreesia Trading Down 3.5%</h2><p>The business's 50 day moving average is $9.82 and its two-hundred day moving average is $14.27. The company has a quick ratio of 1.53, a current ratio of 1.53 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $546.39 million, a P/E ratio of 294.50 and a beta of 0.89. </p><ul><li>Phreesia Stock is a Healthcare IT Play </li></ul><p>Phreesia (NYSE:PHR - Get Free Report) last issued its quarterly earnings results on Monday, March 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.05). Phreesia had a net margin of 0.48% and a return on equity of 3.23%. The firm had revenue of $127.07 million for the quarter, compared to analyst estimates of $126.75 million. During the same quarter last year, the business posted ($0.11) earnings per share. The firm's revenue for the quarter was up 15.9% compared to the same quarter last year.  Analysts expect that  Phreesia, Inc. will post 0.28 EPS for the current year. </p><h2>Insider Buying and Selling at Phreesia</h2><p>In other Phreesia news, General Counsel Allison C. Hoffman sold 6,176 shares of the company's stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $9.06, for a total value of $55,954.56. Following the completion of the sale, the general counsel directly owned 157,309 shares of the company's stock, valued at approximately $1,425,219.54. This represents a 3.78% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Yvonne Hui sold 10,063 shares of the company's stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $9.08, for a total transaction of $91,372.04. Following the completion of the sale, the insider directly owned 25,991 shares of the company's stock, valued at $235,998.28. The trade was a 27.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 50,493 shares of company stock valued at $461,983 over the last 90 days. Insiders own  5.50% of the company's stock. </p><h2>Institutional Trading of Phreesia</h2><p>Institutional investors and hedge funds have recently bought and sold shares of the stock. Pale Fire Capital SE purchased a new stake in  Phreesia during the first quarter valued at about $72,481,000.  Vanguard Group Inc. lifted its stake in  Phreesia by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 5,744,326 shares of the company's stock valued at $97,194,000 after buying an additional 39,540 shares in the last quarter.  Greenhouse Funds LLLP lifted its stake in  Phreesia by 16.8% during the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company's stock valued at $91,317,000 after buying an additional 557,265 shares in the last quarter.  Granahan Investment Management LLC lifted its stake in  Phreesia by 73.8% during the fourth quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company's stock valued at $40,601,000 after buying an additional 1,018,987 shares in the last quarter.  Finally, Franklin Resources Inc. lifted its stake in  Phreesia by 28.8% during the fourth quarter. Franklin Resources Inc. now owns 2,000,082 shares of the company's stock valued at $33,841,000 after buying an additional 446,890 shares in the last quarter. Institutional investors and hedge funds own  92.10% of the company's stock. </p><h2>About Phreesia</h2> (Get Free Report)<p>Phreesia, Inc <span>NYSE: PHR<span></span></span> is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.  </p><p>Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.</p><h2>See Also</h2><ul><li>Five stocks we like better than Phreesia</li><li>AI Consolidation Begins: Blackstone &amp; Google Forge an AI Empire</li><li>USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms</li><li>3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO</li><li>The Great AI Rotation: Cashing In on Data</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Phreesia Right Now?</h2><p>Before you consider Phreesia, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phreesia wasn't on the list.</p><p>While Phreesia currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Phreesia (NYSE:PHR) shares gapped down from $9.17 to $8.84, currently trading at $8.7870. Negative sentiment arises from a class action lawsuit, impacting management credibility. Analysts have lowered price targets, with Wells Fargo setting it at $9.00 and JPMorgan at $16.00. The company reported Q1 earnings of $0.02 EPS, missing estimates. Insider selling has occurred, with insiders owning 5.50% of shares. Institutional trading activity has also been noted.</p>

Market Beat

Phreesia

Wells Fargo

JPMorgan Chase

Waystar

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Phreesia (NYSE:PHR) Shares Gap Down   - Here's Why